Cancer treatments
US6699483B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 7, 2001 |
| Grant date | Mar 2, 2004 |
| Priority date | — |
| Expiry date | Sep 7, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/884
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a product comprised of specific combinations of cell lines intended for use as an allogeneic immunotherapy agent for the treatment of prostate cancer in humans. The heterogeneity of the immunotherapeutic matches the heterogeneity of the antigenic profile in the target prostate cancer and immunises the recipients with many of the potential TAA and TSA which are expressed at various stages of the disease. The invention discloses a vaccine comprising a combination of three different cell lines prepared from primary or metastatic prostate cancer biopsy material. The cell lines are lethally irradiated utilising gamma irradiation at 50-300 Gy to ensure that they are replication incompetent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.